Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the children's oncology group

Journal of Clinical Oncology

Volumn 30, Issue 20, 2012, Pages 2545-2551

  Ebb, David ^a   Meyers, Paul ^c   Grier, Holcombe ^b   Bernstein, Mark ^m   Gorlick, Richard ^d   Lipshultz, Steven E ^e   Krailo, Mark ^h   Devidas, Meenakshi ^f   Barkauskas, Donald A ^h   Siegal, Gene P ^j   Ferguson, William Shay ^k   Letson, George Douglas ^g   Marcus, Karen ^b   Goorin, Allen ^b   Beardsley, Peter ^l   Marina, Neyssa ⁱ  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f CHILDREN S ONCOLOGY GROUP   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j UNIVERSITY OF ALABAMA   (United States)

^k Cardinal Glennon Hospital   (United States)

^l YALE UNIVERSITY   (United States)

^m IWK HEALTH CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE; RAZOXANE; TRASTUZUMAB;

ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC OSTEOSARCOMA; MYELOID LEUKEMIA; NAUSEA; NEUTROPENIA; OSTEOSARCOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; VOMITING;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; OSTEOSARCOMA; RECEPTOR, ERBB-2;

EID: 84864044404     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.4546     Document Type: Article

References (42)

1. Lewis DR, Ries G: Cancers of the bone and joint. SEER Survival Monograph. http://seer.cancer.gov/publications/survival/surv-bone-joint.pdf
2. Meyers PA, Heller G, Healey J, et al: Chemotherapy for nonmetastatic osteosarcoma: The Memorial Sloan Kettering experience. J Clin Oncol 10:5-15, 1992
3. Harris MB, Gieser P, Goorin AM, et al: Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group study. J Clin Oncol 16:3641-3648, 1998 (Pubitemid 28506779)
4. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790, 2002 (Pubitemid 34111386)
5. Kager L, Zoubeck A, Potschger U, et al: Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 21:2011-2018, 2003 (Pubitemid 46606391)
6. Onda M, Matsuda S, Higaki S, et al: ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77:71-78, 1996 (Pubitemid 26002739)
7. Gorlick R, Huvos AG, Heller G, et al: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17:2781-2788, 1999 (Pubitemid 29415235)
8. Scotlandi K, Manara MC, Hattinger CM, et al: Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 41:1349-1361, 2005 (Pubitemid 40813013)
9. Hynes NE: Amplification and overexpression of the erbB-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 4:19-26, 1993
10. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/new oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
11. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991
12. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994 (Pubitemid 24194147)
13. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998 (Pubitemid 28363029)
14. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
15. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
16. Mariani G, Fasolo A, De Benedictis E, et al: Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6:93-104, 2009
17. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node positive, human epidermal growth factor receptor 2-expressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005 (Pubitemid 46657378)
18. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse events in the Herceptin Adjuvant Trial. J Clin Oncol 25:3859-3865, 2007 (Pubitemid 47477261)
19. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol 26:1231-1238, 2008
20. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992
21. Wexler LH, Andrich MP, Venzon D, et al: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362-372, 1996 (Pubitemid 26050996)
22. Swain SM, Whaley FS, Berber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997 (Pubitemid 27167363)
23. Colan SD, Parness IA, Spevak PJ, et al: Developmental modulation of myocardial mechanics: Age and growth-related alterations in afterload and contractility. J Am Coll Cardiol 19:619-629, 1992
24. Lipshultz SE, Easley KA, Orav EJ, et al: Cardiac structure and function in children infected with human immunodeficiency virus: The prospective P2C2 HIV multicenter study. Circulation 97:1246-1256, 1998 (Pubitemid 28169176)
25. Sluysmans T, Colan SD: Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol 99:445-457, 2005 (Pubitemid 41061136)
26. Mair J, Artner-Sworzak E, Lechleitner P, et al: Cardiac troponin T in diagnosis of acute myocardial infarction. Clin Chem 37:845-852, 1991 (Pubitemid 21925927)
27. Trachtenberg BH, Landy DC, Franco VI, et al: Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 32:342-353, 2011
28. Lipshultz SE, Rifai N, Dalton VM, et al: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145-153, 2004 (Pubitemid 38886649)
29. Lipshultz SE, Rifai N, Sallan SE, et al: Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96:2641-2648, 1997 (Pubitemid 27451357)
30. Maeda K, Tsuramoto T, Wada A, et al: Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135:825-832, 1998 (Pubitemid 28237306)
31. Favilli S, Frenos S, Lasagni D, et al: The use of B-type natriuretic peptide in pediatric patients: A review of the literature. J Cardiovasc Med 10:298-302, 2009
32. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 2002
33. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600-1606, 1986 (Pubitemid 16118216)
34. Goorin AM, Harris MB, Bernstein M, et al: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group trial. J Clin Oncol 20:426-433, 2002 (Pubitemid 34072525)
35. Zhou H, Randall RL, Brothman AR, et al: HER-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 25:27-32, 2003 (Pubitemid 36070961)
36. Fellenberg J, Krauthoff A, Pollandt A, et al: Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser micro-dissected paraffin-embedded tissue. Lab Invest 84:113-121, 2004 (Pubitemid 41656440)
37. Hughes DP, Thomas DG, Giordano TJ, et al: Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64:2047-2053, 2004 (Pubitemid 38339452)
38. Akatsuka T, Wada T, Kokai Y, et al: ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94:1397-1404, 2002 (Pubitemid 34212632)
39. Maitra A, Wanzer D, Weinberg AG, et al: Amplification of the HER2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 92:677-683, 2001 (Pubitemid 32735206)
40. Thomas DG, Giordano TJ, Sanders D, et al: Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 8:788-793, 2002 (Pubitemid 34742109)
41. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al: Overexpression of the HER-2 oncogene does not play a role in high grade osteosarcomas. Eur J Cancer 40:963-970, 2004 (Pubitemid 38496251)
42. Kilpatrick SE, Geisinger KR, King TS, et al: Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 14:1277-1283, 2001 (Pubitemid 33151171)